Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study.
Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study.
复制标题
口服谷氨酰胺预防癌症患者多西紫杉醇或紫杉醇相关的味觉改变：一项随机、安慰剂对照、双盲研究。
DOI：
--
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
S. Gillessen
中科院分区：
文献类型：
--
作者：
F. Strasser;R. Demmer;C. Böhme;S. H. Schmitz;B. Thuerlimann;T. Cerny;S. Gillessen
味觉改变（味觉障碍）是一种未被认识到的与紫杉烷化疗（TaxCh）相关的毒性，缺乏标准治疗。我们研究了口服谷氨酰胺预防首次接受TaxCh的患者的发音障碍。成年患者从TaxCh的第1天开始随机接受30 g/天的谷氨酰胺或安慰剂（麦芽糊精）。每天用视觉模拟量表（VAS）测量患儿的发音障碍。在每个化疗周期，客观（酸、甜、咸、苦）和主观（四类量表）的味道和毒性（国家癌症研究所共同毒性标准，v.3）进行评估。治疗口腔炎和缺锌。对于主要结果，使用线性混合模型分析重复的阅读障碍评分。用广义估计方程对每个客观或主观味觉项目的重复数据进行分析。在52例随机患者中，41例完成了治疗（中位研究持续时间为74天）。在基线时，谷氨酰胺组（n = 21）和安慰剂组（n = 20）在年龄（64岁）、性别（32%男性）、肿瘤类型、化疗（多西紫杉醇，44%；紫杉醇，56%）、方案（每周，78%；每3周，22%）、治疗意图（15%辅助）、认知障碍（VAS, 11/100）和味觉识别（88%）方面具有可比性。周围神经病变1-2级24例；没有一个是3级。谷氨酰胺和安慰剂在最大读写困难和从基线开始增加方面没有差异，线性时间效应不显著。单独的亚组分析对基线阅读障碍<或=11或>11的患者没有改变结果。客观或主观味觉测试没有差异，也没有不良事件。与安慰剂相比，口服谷氨酰胺不能预防或减少与TaxCh相关的主观味觉障碍或味觉感知改变。谷氨酰胺在紫杉烷相关的读写障碍的支持治疗中的作用似乎有限。
Taste alteration (dysgeusia), an underrecognized toxicity associated with taxane-based chemotherapy (TaxCh), lacks standard treatment. We investigated prevention of dysgeusia with oral glutamine in patients undergoing first-time TaxCh. Adult patients were randomized to receive either 30 g/day glutamine or placebo (maltodextrin) from day 1 of TaxCh. Dysgeusia was measured daily with a visual analogue scale (VAS). On each chemotherapy cycle, objective (sour, sweet, salty, bitter) and subjective (four-category scale) taste and toxicity (National Cancer Institute Common Toxicity Criteria, v.3) were assessed. Stomatitis and zinc deficiency were treated. For primary outcomes, repeated dysgeusia scores were analyzed with a linear mixed model. Repeated data on each objective or subjective taste item were analyzed with a generalized estimating equation. Of 52 patients randomized, 41 completed treatment (median study duration, 74 days). At baseline, the glutamine (n = 21) and placebo (n = 20) groups were comparable for age (64 years), gender (32% men), tumor types, chemotherapy (docetaxel, 44%; paclitaxel, 56%), schedule (weekly, 78%; 3-weekly, 22%), treatment intention (15% adjuvant), dysgeusia (VAS, 11/100), and taste recognition (88%). Twenty-four patients had peripheral neuropathy grades 1-2; none had grade 3. Glutamine and placebo were not different for maximal dysgeusia and increase from baseline, with an insignificant linear time effect. Separate subgroup analyses for patients with baseline dysgeusia < or =11 or >11 did not alter the results. Objective or subjective taste tests were not different, neither were adverse events. Compared with placebo, oral glutamine did not prevent or decrease subjective taste disturbances or altered taste perception associated with TaxCh. The role of glutamine in supportive care of taxane-associated dysgeusia seems limited.
影响因子：
12.4
作者：
Kirchmair, Rudolf;Tietz, Anne B.;Losordo, Douglas W.
通讯作者：
Losordo, Douglas W.
用谷氨酰胺减少紫杉醇引起的周围神经病变。
DOI：
--
发表时间：
2001
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research.
影响因子：
--
作者：
Vahdat,L;Papadopoulos,K;Lange,D;Leuin,S;Kaufman,E;Donovan,D;Frederick,D;Bagiella,E;Tiersten,A;Nichols,G;Garrett,T;Savage,D;Antman,K;Hesdorffer,CS;Balmaceda,C
通讯作者：
Balmaceda,C